IBISWorld Platform
Answer any industry question in minutes with our entire database at your fingertips.
Pharmaxis Limited
Pharmaxis is a Public Company that generates the majority of its income from the Scientific Research Services industry. In 2025 the company generated total revenue of $7,630,000 including sales and other revenue. The exact number of employees for this organisation is not available. The Chief Executive of Pharmaxis is Unknown Gary Jonathan Phillips whose official title is CHIEF EXECUTIVE OFFICER. The Chairman of Pharmaxis is Mr Malcolm McComas whose official title is Independent Chairman. Pharmaxis Limited is an ASX-listed company that is a drug developer for combatting inflammatory and fibrotic diseases in the pharmaceuticals industry. The Company develops two main drug products: Bronchitol (the treatment for cystic fibrosis, approved and marketed in Europe, Russia, Australia and the United States of America) Aridol (a bronchial challenge test for the diagnosis and examination of asthma, approved and marketed in the United States of America, Europe, Australia, Canada and Asia)
Access this data your way
The Pharmaxis Limited Industry analysis is available in multiple formats to fit seamlessly into your workflow.
API Data Delivery
Feed trusted, human-driven industry intelligence straight into your platform.
Integrations
Streamline your workflow with IBISWorld’s intelligence built into your toolkit.
What's included in this industry analysis
IBISWorld's research coverage on the Pharmaxis Limited includes market sizing, forecasting, data and analysis. The most recent publication will be as current as of March 2026.
Company Details
What’s this enterprise profile about?
Pharmaxis Limited, trading as Pharmaxis, operates under the ABN 75 082 811 630 and was incorporated on 29 May 1998. Pharmaxis Limited trades on the Australian Securities Exchange under the ticker code ASX:PXS. Pharmaxis Limited primarily operates in the Pharmaceutical Product Manufacturing industry in Australia.
Key Personnel
What’s included in the Key Personnel chapter?
The Key Personnel chapter outlines the principal leadership positions within Pharmaxis Limited, including the Chairman, Board members, Chief Executive Officer, and other key management personnel. It provides an overview of the company’s governance and executive structure, along with a breakdown of gender diversity across leadership roles, offering insight into the composition of the organisation’s senior team.
Financials
What’s included in the Financials chapter?
The Financials chapter presents Pharmaxis Limited’s historical financial performance, including detailed profit and loss statements outlining sales revenue, cost of sales, and profitability. It also incorporates balance sheet data, providing a breakdown of assets and liabilities, as well as additional financial metrics such as the number of shares on issue. Together, these disclosures offer a comprehensive view of the company’s financial position and performance over time.
Growth & Ratios
What’s included in the Growth & Rations chapter?
The Growth & Ratios chapter provides historical data on key financial performance indicators, enabling an assessment of the company’s operational efficiency, profitability, and financial structure over time. Metrics covered include return on equity, return on assets, profit margins, revenue per employee, as well as gearing and leverage ratios, offering a comprehensive view of performance trends and capital management.
Operating Segments
What’s included in the Operating Segments chapter?
The Operating Segments chapter provides an overview of the revenue composition and asset allocation across the various industries in which Pharmaxis Limited operates. It offers insights into how the company’s financial performance is distributed among its core business segments, highlighting the relative contribution of each industry to total revenue.
Competitor Benchmarking
What’s included in the Competitor Benchmarking chapter?
The Competitor Benchmarking chapter includes a comparative assessment of Pharmaxis Limited’s key financial, growth, and valuation ratios against industry averages to evaluate its competitive position. It analyses valuation metrics such as price-to-earnings, price-to-book, enterprise value to EBITDA, and enterprise value to sales, alongside core financial indicators including liquidity ratios and profitability measures.
Industries of Operation
What’s included in the Industries of Operation chapter?
The Industries of Operation chapter outlines Pharmaxis Limited’s market share across the industries in which it operates. Each industry profile includes a comprehensive overview featuring data on total market size, the number of enterprises, industry concentration levels, and overall turnover. This analysis provides context for the company’s competitive position and scale within each relevant market.
Shareholders
What’s included in the Shareholders chapter?
The Shareholders chapter provides a breakdown of the ownership structure of Pharmaxis Limited, identifying key shareholders and outlining their respective ownership interests. This section offers insight into the concentration of shareholdings, the presence of institutional or strategic investors, and the overall distribution of equity within the company.
Subsidiaries
What’s included in the Subsidiaries chapter?
The Subsidiaries chapter provides an overview of the companies and business entities that are wholly or partially owned by Pharmaxis Limited. It outlines the ownership structure of each subsidiary, offering insight into the broader corporate group and how these entities contribute to the company’s overall activities and performance.
History
What’s included in the History chapter?
The History chapter presents a overview of Pharmaxis Limited’s development, highlighting key milestones and significant corporate events since its incorporation. It includes the company’s incorporation date and outlines major strategic, operational, and structural developments, providing context for its evolution and current market position.
Trusted by industry professionals
More than 6,000 businesses use IBISWorld to shape local and global economies
We were able to supplement our reports with IBISWorld’s information from both a qualitative and quantitative standpoint. All of our reporting now features some level of IBISWorld integration.
IBISWorld delivers the crisp business knowledge we need to drive our business. Whether it be serving up our major clients, winning new business or educating on industry issues, IBISWorld brings real value.
IBISWorld has revolutionised business information — which has proved commercially invaluable to exporters, investors and public policy professionals in Australia and overseas.
When you’re able to speak to clients and be knowledgeable about what they do and the state that they operate in, they’re going to trust you a lot more.
Frequently Asked Questions
What is Pharmaxis Limited?
Pharmaxis Limited is an ASX-listed company that is a drug developer for combatting inflammatory and fibrotic diseases in the pharmaceuticals industry. The Company develops two main drug products: Bronchitol (the treatment for cystic fibrosis, approved and marketed in Europe, Russia, Australia and the United States of America) Aridol (a bronchial challenge test for the diagnosis and examination of asthma, approved and marketed in the United States of America, Europe, Australia, Canada and Asia)
What industry does Pharmaxis Limited operate in?
Pharmaxis Limited, trading as Pharmaxis, is a Public Company that generates the majority of its income from the Pharmaceutical Product Manufacturing industry in Australia.
Where is Pharmaxis Limited located?
Murray Cod Australia Limited company is based at 20 Rodborough Road, Frenchs forest, New South Wales, Australia.
Who is the CEO of Pharmaxis Limited?
The OPERATIONS DECISION MAKER of Pharmaxis Limited is Gary Jonathan Phillips and the OPERATIONS DECISION MAKER is Brett Charlton.
What was Pharmaxis Limited’s revenue in 2025?
In 2025, Pharmaxis Limited generated total revenue of approximately $7.6 million.
Cut through the noise with intelligence you can trust
